Compare RNTX & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | XBP |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | 10 | 10998 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 47.0M |
| IPO Year | N/A | N/A |
| Metric | RNTX | XBP |
|---|---|---|
| Price | $1.02 | $2.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $5.00 |
| AVG Volume (30 Days) | ★ 841.5K | 18.0K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.59 |
| Revenue Next Year | N/A | $5.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.41 |
| 52 Week High | $2.18 | $8.55 |
| Indicator | RNTX | XBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 35.53 |
| Support Level | N/A | $2.00 |
| Resistance Level | $1.33 | $3.00 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 24.94 | 26.50 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine business process automation and enable digital transformation.